Alise Reicin Net Worth

Alise Reicin biography

Dr. Alise S. Reicin M.D. serves as Independent Director of the Company. Dr. Reicin served as President, Global Clinical Development at Celgene Corporation, a pharmaceutical company, from November 2018 to December 2019. Prior to Celgene, she served as Head of Global Clinical Development at EMD Serono, a pharmaceutical company, from May 2015 through October 2018. Prior to EMD Serono, Dr. Reicin served as VP, Program Leadership Oncology at Merck and Co., a pharmaceutical company. She holds a B.A. in Biochemistry from Barnard College of Columbia University and an M.D. from Harvard Medical School. Reicin’s clinical expertise and leadership roles in the biotechnology and biopharmaceutical industries provide her with the qualifications to serve as a director of our Company.

What is the salary of Alise Reicin?

As the Independent Director of Homology Medicines Inc, the total compensation of Alise Reicin at Homology Medicines Inc is $372,528. There are 7 executives at Homology Medicines Inc getting paid more, with Arthur Tzianabos having the highest compensation of $5,062,880.

How old is Alise Reicin?

Alise Reicin is 59, he's been the Independent Director of Homology Medicines Inc since 2019. There are 6 older and 12 younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.

What's Alise Reicin's mailing address?

Alise's mailing address filed with the SEC is C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD, MA, 01730.

Insiders trading at Homology Medicines Inc

Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management... a Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.

What does Homology Medicines Inc do?

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Homology Medicines Inc executives and stock owners

Homology Medicines Inc executives and other stock owners filed with the SEC include:

• Arthur Tzianabos,
  President, Chief Executive Officer, Director
• Tim Kelly,
  Chief Technical Operations Officer
• Albert Seymour,
  Chief Scientific Officer
• W. Bradford Smith,
  Chief Financial Officer, Treasurer and Secretary
• Dr. Arthur O. Tzianabos Ph.D.,
  Pres, CEO & Director
• Dr. Albert Seymour Ph.D.,
  Chief Scientific Officer
• W. Bradford Smith CPA, M.B.A.,
  CFO & Treasurer
• Alise Reicin,
  Independent Director
• Kush Parmar,
  Independent Director
• Mary Thistle,
  Independent Director
• Richard Gregory,
  Independent Director
• Matthew Patterson,
  Independent Director
• Steven Gillis,
  Independent Director
• Jeffrey Poulton,
  Director
• Gabriel Cohn,
  Chief Medical Officer
• Cara Mayfield,
  Director of Corp. Communications
• Dr. Deborah Kinch Ph.D.,
  Chief Devel. Officer
• Dr. Julie Jordan M.D.,
  Sr. VP and Head of Clinical Devel. & Operations
• Michael Blum M.B.A.,
  Chief Commercial Officer
• Dr. Gabriel M. Cohn M.B.A., M.D.,
  Chief Medical Officer
• Melissa Gelormini,
  VP of HR
• Theresa McNeely,
  Chief Communications Officer & Patient Advocate
• Dr. Paul Alloway J.D., Ph.D.,
  Chief Legal Officer & Sec.
• Timothy P. Kelly M.B.A.,
  Chief Operating Officer
• Dr. Saswati Chatterjee Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Ventures Iv, L.P.5 Am Co In...,
  
• Ventures Iv, L.P.5 Am Partn...,
  
• Institutes For Bio Medical ...,
  
• Ventures, Llcvv Manager Llc...,
  
• Holdings (Private) Ltd Full...,
  
• Cameron Wheeler,
  Director
• Siyamak Rasty,
  Chief Operating Officer
• James Edeerfield Management...,
  
• James Edeerfield Management...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Springs Capital Management ...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Charles Jr Michaud,
  See Remarks
• Paul Alloway,
  See Remarks
• Michael Lee Blum,
  Chief Commercial Officer
• Julie Jordan,
  Chief Medical Officer